The group’s principal activities include developing and manufacturing commercial and clinical APIs. The group’s services include research and development, multi step process development, scale up and validation, and analytical method development. The products of the group include fentanyl base, fentanyl citrate, hydrocodone, and sodium butabarbitol, tetrahydrocannabinol and exemestane. The group operates from the United States.
